Chieng David, Canovas Rodrigo, Segan Louise, Sugumar Hariharan, Voskoboinik Aleksandr, Prabhu Sandeep, Ling Liang-Han, Lee Geoffrey, Morton Joseph B, Kaye David M, Kalman Jonathan M, Kistler Peter M
Clinical Electrophysiology Research Laboratory, Baker Heart and Diabetes Research Institute, 55 Commercial Road, Melbourne 3004, Australia.
Department of Cardiology, Alfred Hospital, 55 Commercial Road, Melbourne 3004, Australia.
Eur J Prev Cardiol. 2022 Dec 7;29(17):2240-2249. doi: 10.1093/eurjpc/zwac189.
Epidemiological studies report the beneficial effects of habitual coffee consumption on incident arrhythmia, cardiovascular disease (CVD), and mortality. However, the impact of different coffee preparations on cardiovascular outcomes and survival is largely unknown. The aim of this study was to evaluate associations between coffee subtypes on incident outcomes, utilizing the UK Biobank.
Coffee subtypes were defined as decaffeinated, ground, and instant, then divided into 0, <1, 1, 2-3, 4-5, and >5 cups/day, and compared with non-drinkers. Cardiovascular disease included coronary heart disease, cardiac failure, and ischaemic stroke. Cox regression modelling with hazard ratios (HRs) assessed associations with incident arrhythmia, CVD, and mortality. Outcomes were determined through ICD codes and death records. A total of 449 563 participants (median 58 years, 55.3% females) were followed over 12.5 ± 0.7 years. Ground and instant coffee consumption was associated with a significant reduction in arrhythmia at 1-5 cups/day but not for decaffeinated coffee. The lowest risk was 4-5 cups/day for ground coffee [HR 0.83, confidence interval (CI) 0.76-0.91, P < 0.0001] and 2-3 cups/day for instant coffee (HR 0.88, CI 0.85-0.92, P < 0.0001). All coffee subtypes were associated with a reduction in incident CVD (the lowest risk was 2-3 cups/day for decaffeinated, P = 0.0093; ground, P < 0.0001; and instant coffee, P < 0.0001) vs. non-drinkers. All-cause mortality was significantly reduced for all coffee subtypes, with the greatest risk reduction seen with 2-3 cups/day for decaffeinated (HR 0.86, CI 0.81-0.91, P < 0.0001); ground (HR 0.73, CI 0.69-0.78, P < 0.0001); and instant coffee (HR 0.89, CI 0.86-0.93, P < 0.0001).
Decaffeinated, ground, and instant coffee, particularly at 2-3 cups/day, were associated with significant reductions in incident CVD and mortality. Ground and instant but not decaffeinated coffee was associated with reduced arrhythmia.
流行病学研究报告了习惯性饮用咖啡对心律失常、心血管疾病(CVD)及死亡率的有益影响。然而,不同咖啡制品对心血管结局和生存率的影响很大程度上尚不清楚。本研究的目的是利用英国生物银行评估不同类型咖啡与发病结局之间的关联。
咖啡类型定义为脱咖啡因咖啡、研磨咖啡和速溶咖啡,然后分为每天0杯、<1杯、1杯、2 - 3杯、4 - 5杯和>5杯,并与不喝咖啡者进行比较。心血管疾病包括冠心病、心力衰竭和缺血性中风。采用Cox回归模型及风险比(HRs)评估与心律失常、CVD及死亡率的关联。结局通过国际疾病分类代码和死亡记录确定。共有449563名参与者(中位年龄58岁,女性占55.3%)被随访了12.5±0.7年。每天饮用1 - 5杯研磨咖啡和速溶咖啡与心律失常显著减少相关,但脱咖啡因咖啡无此关联。研磨咖啡每天饮用4 - 5杯时风险最低[HR 0.83,置信区间(CI)0.76 - 0.91,P < 0.0001],速溶咖啡每天饮用2 - 3杯时风险最低(HR 0.88,CI 0.85 - 0.92,P < 0.0001)。与不喝咖啡者相比,所有类型的咖啡均与CVD发病率降低相关(脱咖啡因咖啡每天饮用2 - 3杯时风险最低,P = 0.0093;研磨咖啡,P < 0.0001;速溶咖啡,P < 0.0001)。所有类型的咖啡均使全因死亡率显著降低,脱咖啡因咖啡每天饮用2 - 3杯时风险降低幅度最大(HR 0.86,CI 0.81 - 0.91,P < 0.0001);研磨咖啡(HR 0.73,CI 0.69 - 0.78,P < 0.0001);速溶咖啡(HR 0.89,CI 0.86 - 0.93,P < 0.0001)。
脱咖啡因咖啡、研磨咖啡和速溶咖啡,尤其是每天饮用2 - 3杯时,与CVD发病率和死亡率显著降低相关。研磨咖啡和速溶咖啡而非脱咖啡因咖啡与心律失常减少相关。